Helix BioPharma Announces Appointment of Director
13 Junio 2013 - 4:05PM
Marketwired
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a
biopharmaceutical company developing drug candidates for the
prevention and treatment of cancer, today announced the appointment
of Stace Wills to the board of directors. Mr. Wills is a resident
Canadian and his appointment was effective June 12, 2013.
Commenting on the appointment, Mario Gobbo, Chairman of the
Board of Helix, said, "Mr. Wills has over 20 years of experience in
the life sciences, biotech and technology sectors and I look
forward to the insights he will bring to our board and to working
with him as Helix pursues its product development initiatives."
Helix also announced that Andrew J. MacDougall, who had agreed
to serve on the board of directors on an interim basis pending the
appointment of a resident Canadian director to satisfy the
statutory requirement for resident Canadians to comprise at least
25% of Helix's board of directors, voluntarily resigned as a
director following the appointment of Mr. Wills. Mr. Gobbo
commented, "Mr. MacDougall's interim service on the board has
provided us with time to complete our director recruitment process.
We thank him for his contributions as a director and look forward
to his continued service as counsel to the company."
Following the appointment of Mr. Wills and the resignation of
Mr. MacDougall, the board is comprised of six directors, five of
whom are independent of Helix.
About Helix BioPharma Corp.
Helix BioPharma Corp. is a biopharmaceutical company
specializing in the field of cancer therapy. The company is
actively developing innovative products for the prevention and
treatment of cancer based on its proprietary technologies. Helix's
product development initiatives include its novel L-DOS47 new drug
candidate and its Topical Interferon Alpha-2b. Helix is currently
listed on the TSX and FSE under the symbol "HBP".
Investor Relations: Helix BioPharma Corp. Tel: 905
841-2300 Email: ir@helixbiopharma.com
Helix BioPharma (TSX:HBP)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Helix BioPharma (TSX:HBP)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024